Has Dan Gzesh, MD received payments from drug or device companies?

Yes. Drug and device makers reported $11,206 in general payments to Dan Gzesh, MD across 220 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Dan Gzesh, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Dan Gzesh, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Dan Gzesh, MD

Neurology · Abington, PANPI 1417984923

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (43.0%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Eisai Inc. accounts for 64.5% of it on its own, with 52 other manufacturers making up the rest. Reporting peaked in 2024 at $5,516 and has fallen 55.1% since, to $2,476 in 2025.

$11,206in general payments, 2019–2025

Across 220 payments — averaging $50.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Eisai Inc.$7K
AbbVie$631
Supernus Pharmaceuticals, Inc.$384
Biogen$329
AstraZeneca$244
Argenx US, Inc.$206
plus $2K from 47 others

What the payments were for

Consulting fees$4,81543%
Speaking & faculty fees$1,75816%
Travel & lodging$4264%
Food & beverage$4,20738%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Eisai Inc.	19	$7,231
AbbVie(2 entities)	28	$631
Supernus Pharmaceuticals, Inc.	33	$384
Biogen	9	$329
AstraZeneca(2 entities)	7	$244
Argenx US, Inc.	7	$206
CSL Behring	9	$192
Akcea Therapeutics, Inc.	3	$188
Biohaven Pharmaceuticals, Inc.	11	$144
Novartis	10	$121
Sanofi	6	$99
Upsher-smith Laboratories LLC	4	$82
Lilly USA, LLC	5	$78
UCB, Inc.	4	$78
Adamas Pharmaceuticals, Inc.	3	$64
Lundbeck LLC	4	$63
EMD Serono, Inc.	4	$63
Grifols USA, LLC	3	$53
Genentech USA, Inc.	2	$51
Jazz Pharmaceuticals Inc.	2	$50
Otsuka Pharmaceutical Development & Commercialization, Inc.	1	$50
Sunovion Pharmaceuticals Inc.	3	$45
Acorda Therapeutics, Inc	2	$43
Merz Pharmaceuticals, LLC	2	$43
Teva Pharmaceuticals USA, Inc.	3	$43
Amgen	2	$40
Otsuka America Pharmaceutical, Inc.	2	$40
Amneal Pharmaceuticals LLC	2	$40
Neurelis, Inc.	2	$34
E.r. Squibb & Sons, L.L.C.	2	$33
Neurocrine Biosciences, Inc.	2	$32
Vertical Pharmaceuticals, LLC	2	$30
Springworks Therapeutics, Inc.	1	$30
Hoffmann-la Roche Limited	1	$25
Corium, LLC	2	$24
Abbott	1	$24
Pfizer	1	$21
Boston Scientific	1	$21
Aucta Pharmaceuticals, Inc.	1	$20
Scilex Pharmaceuticals Inc.	1	$20
Avanir Pharmaceuticals, Inc.	1	$18
Greenwich Biosciences, Inc.	1	$17
SK Life Science, Inc.	1	$17
Mallinckrodt Hospital Products Inc.	1	$16
Kyowa Kirin, Inc.	1	$16
Mallinckrodt Enterprises LLC	1	$16
Bristol Myers Squibb	1	$16
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	1	$16
Tanabe Pharma America, Inc.	1	$15
Ipsen Biopharmaceuticals, Inc	1	$15
Arbor Pharmaceuticals, Inc.	1	$13
Merck	1	$12
MDD US Operations, LLC	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Leqembi$6,876
SOLIRIS$134
ADUHELM$107

How this compares

$11,206 in reported general payments places this provider in the 80th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$64,326

Medicare patients

276

Services billed

1,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Memantine Hcl	15	$2,259
Donepezil Hcl	106	$824
Escitalopram Oxalate	14	$97

Paid to pharmacies, not to this prescriber.

Other neurology in Abington

Brad KleinAbington$927K
John KhouryAbington$686K
David WeismanAbington$275K
Daniel KremensPhiladelphia$1.8M
Thomas LeistPhiladelphia$1.4M
Jill Giordano FarmerPhiladelphia$1.2M
Ravi DukkipatiYork$936K
Stephanie Nahas-GeigerPhiladelphia$786K
Amit Bar-OrPhiladelphia$596K
Behrang SaminejadAllentown$594K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →